Corveus Medical

Medical | Treatment of Congestive Heart Failure

health AI/medtech (cardiovascularneuromodulation)

Visit website

StagePre-seed/Accelerator-backed

YC batchYC W22

Raised$760K - $1M

Employees5

LocationHouston, TX

About

We are a Fogarty backed medical device company that is developing a minimally invasive, catheter-based technology for nerve ablation. (YC W22 | MedTech Innovator 22)

Product

Value proposition: Corveus’ minimally-invasive solution deactivates a nerve that is a root cause behind heart failure progression, enabling treatment for patients with few options.
Target customers: Hospitals and cardiology centers performing interventional procedures for heart failure

Founders

Tyler Melton — CEO and Co-Founder
Ishan Kamat, MD — CMO and Co-Founder

Products

Catheter-based nerve deactivation system for heart failure

Key features

Minimally-invasive catheter-based nerve deactivationTargeted sympathetic nerve ablationNerve deactivation confirmed intra-procedurallyPotential lasting patient benefit

Technologies

Catheter-based ablationNeuromodulationVenous access pathway utilizationIn-procedure nerve activity confirmation

Target conditions

Congestive heart failureHFpEF (heart failure with preserved ejection fraction)Heart failure progression

Care settings

hospitalclinicOR (operating room)invasive procedure

Investors

MassChallenge U.S.National Science FoundationMedTech InnovatorY CombinatorCreative Destruction Lab SpaceFogarty Innovation

News

Corveus Medical Joins Fogarty Innovation to Tackle Heart Failure · 2024-08-30T00:00:00.000Z
A Biodesign Program Founder's Journey with Aaron Glick and Tyler... · 2025-07-09T00:00:00.000Z
6 Houston health tech startups making major advancements right now · 2025-10-22T00:00:00.000Z
TMC Innovation Companies · 2024-07-27T00:00:00.000Z
6 Houston health tech startups making major advancements right now - NEWSx.io · 2025-10-22T07:00:00.000Z
2025 Houston Innovation Awards finalists: Health-tech Business – Pulse Bliss · 2025-10-26T07:23:29.000Z